Table 4 |
||||||
|
Univariate and multivariate analysis of survival time after IMLN recurrence |
||||||
|
Factors |
N |
Univariate analysis |
Multivariate analysis |
|||
|
|
||||||
|
Median (m) |
p-value |
HR |
95%CI |
p-value |
||
|
|
||||||
|
As first site of metastasis |
0.407 |
NS |
||||
|
Yes |
121 |
34 |
||||
|
No |
12 |
64 |
||||
|
Size of IMLN |
0.984 |
NS |
||||
|
≤4 cm |
116 |
51 |
||||
|
>4 cm |
17 |
38 |
||||
|
DFI of IMLN recurrence |
0.001* |
1.4 |
0.7- 2.9 |
0.342 |
||
|
<2 y |
44 |
31 |
||||
|
≥2 y |
89 |
63 |
||||
|
Concurrent metastasis |
0.024* |
0.7 |
0.4- 0.9 |
0.031* |
||
|
No and local |
73 |
61 |
||||
|
Visceral or bone |
60 |
32 |
||||
|
Endocrine therpay |
0.000* |
0.2 |
0.1- 0.5 |
0.001* |
||
|
Yes |
54 |
78 |
||||
|
No |
24 |
26 |
||||
|
Chemotherapy |
0.078 |
NS |
||||
|
Yes |
72 |
34 |
||||
|
No |
61 |
62 |
||||
|
Radiotherapy& |
0.04* |
0.3 |
0.1- 0.9 |
0.026* |
||
|
Yes |
59 |
63 |
||||
|
No |
74 |
32 |
||||
|
|
||||||
|
&Radiotherapy included the patients who received RT as initial (7 cases) and palliative (52 cases) treatment *p < 0.05 |
||||||
|
Chen et al. BMC Cancer 2010 10:479 doi:10.1186/1471-2407-10-479 |
||||||
